首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CSF3 |
| Uniprot No | P09919 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 31-204aa |
| 氨基酸序列 | TPLGPASSLP QSFLLKCLEQ VRKIQGDGAA LQEKLCATYK LCHPEELVLL GHSLGIPWAP LSSCPSQALQ LAGCLSQLHS GLFLYQGLLQ ALEGISPELG PTLDTLQLDV ADFATTIWQQ MEELGMAPAL QPTQGAMPAF ASAFQRRAGG VLVASHLQSF LEVSYRVLRH LAQP |
| 预测分子量 | 18.7 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下为CSF3(重组人粒细胞集落刺激因子，G-CSF)相关文献的简要信息：
1. **文献名称**： *Filgrastim (r-metHuG-CSF) in patients with chemotherapy-induced febrile neutropenia*
**作者**： Gabrilove J.L. 等
**摘要**：研究验证了重组G-CSF(Filgrastim)在化疗后发热性中性粒细胞减少症患者中的疗效，显示其显著缩短中性粒细胞恢复时间并降低感染风险。
2. **文献名称**： *Pegfilgrastim for prevention of chemotherapy-induced neutropenia in adults*
**作者**： Holmes F.A. 等
**摘要**：比较聚乙二醇化长效G-CSF(Pegfilgrastim)与短效制剂的疗效，证实单次注射长效制剂在预防化疗后中性粒细胞减少的效果相当，且患者依从性更高。
3. **文献名称**： *Granulocyte colony-stimulating factor mobilization of hematopoietic stem cells*
**作者**： Anderlini P. 等
**摘要**：探讨G-CSF在造血干细胞动员中的应用，证明其通过增加外周血干细胞数量，显著提升自体或异体移植成功率。
4. **文献名称**： *Biosimilar filgrastim in healthy volunteers*
**作者**： Al-Sabbagh A. 等
**摘要**：评估生物类似药G-CSF与原研药的安全性和药代动力学特征，证实两者在健康人群中具有生物等效性，为临床应用提供依据。
以上文献涵盖重组G-CSF的基础研究、长效制剂优化、干细胞动员及生物类似药开发等关键方向。
CSF3 (Colony-Stimulating Factor 3), also known as granulocyte colony-stimulating factor (G-CSF), is a glycoprotein cytokine critical for regulating neutrophil production and function. Naturally produced by various cells, including macrophages and endothelial cells, it binds to the G-CSF receptor on myeloid progenitor cells, stimulating their proliferation, differentiation, and survival. This process is vital for maintaining neutrophil homeostasis and enhancing innate immunity against infections.
Recombinant CSF3 (rhG-CSF) is a bioengineered version developed through genetic modification. The human CSF3 gene is inserted into expression systems like *E. coli* or mammalian cells, enabling large-scale production. Filgrastim, a non-glycosylated form from *E. coli*, and pegfilgrastim, its PEGylated counterpart with prolonged activity, are widely used clinically. These analogs mimic natural G-CSF’s biological activity but offer improved stability and pharmacokinetics.
Clinically, rhG-CSF is pivotal in managing chemotherapy-induced neutropenia, reducing infection risks by accelerating neutrophil recovery. It also mobilizes hematopoietic stem cells (HSCs) from bone marrow to peripheral blood for collection in stem cell transplantation. Additionally, it treats congenital or chronic neutropenia, enhancing patients' quality of life. Research continues to explore its potential in other conditions, such as tissue repair and immune modulation.
Despite its benefits, rhG-CSF therapy may cause side effects like bone pain or splenomegaly. Ongoing studies aim to optimize dosing, minimize adverse effects, and expand therapeutic applications. As a cornerstone of supportive care in oncology and hematology, recombinant CSF3 exemplifies the successful translation of molecular biology into clinical practice, addressing critical unmet needs in immune-related disorders.
×
